Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2 …
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy / G, Galli; C, Proto; D, Signorelli; M, Imbimbo; Ferrara, R; A, Prelaj; A De, Toma; M, Ganzinelli; N, Zilembo; F de, Braud; Mc, Garassino; G Lo, Russo. - In: FUTURE ONCOLOGY. - ISSN 1744-8301. - 9:5(2019), pp. 1143-1161. [10.2217/fon-2019-0055]
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy
FERRARA R;
2019-01-01
Abstract
Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2 …I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
